ETON PHARMACEUTICALS INC (ETON)

Super-investor holdings · 2026 Q2

Source: SEC Form 13F filings for the quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. 13F filings cover long positions only and arrive up to 45 days after quarter-end.

All institutions · Form 13F

Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).

Insider trading · Form 4

0 insiders bought on the open market in the last 90 days (0 purchases, $0), against 15 sales by 4 insiders ($16.5M).

Source: SEC Form 4 filings, as of Oct 3, 2026. Open-market transactions only.

Politician trading · U.S. House

Data unavailable — no House STOCK Act transactions for this ticker were parsed in the current window (as of Oct 3, 2026).

Screens & lenses

Financial Screens

· Gross Profitability (Novy-Marx) — High gross profit relative to total assets

Chart Signals

· Monthly Uptrend — Price above its 12-month moving average

· Top Relative Strength — Top 20% of the universe by 6-month return

Red Flags

· Distress Risk (Altman Z″) — Altman Z″-Score below 1.10

· Auditor Change (8-K 4.01) — Last 2 years: an auditor change filing (8-K Item 4.01)

Key figures

· Gross Profitability (Novy-Marx) — Gross profit / assets: 46.4% · Gross margin: 53.5%

· Distress Risk (Altman Z″) — Z″-Score: -2.05 · Working capital / assets: 0.24 · Retained earnings / assets: -1.22 · EBIT / assets: -0.01 · Equity / liabilities: 0.40

· Auditor Change (8-K 4.01) — Latest event: Jun 20, 2025 · Events in 2 yrs: 1

Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.